News Releases

For years, researchers have been trying to target a gene called MYC that is known to drive tumor growth in multiple cancer types when it is mutated or over-expressed, but hitting that target successfully has proven difficult. Now researchers in the Perelman School of Medicine of the University of Pennsylvania have identified a new pathway that works as a partner to MYC and may be its Achilles’ Heel.

Treating prostate cancer with higher doses of proton therapy over a shorter amount of time leads to similar outcomes when compared to standard dose levels and treatments and is safe for patients, according to a new study examining the risk of long-term side-effects from the treatment.

Simply introducing a default physician order — a “nudge” — into electronic health records (EHRs) cut the use of unnecessary daily imaging in half during palliative radiation therapy sessions for patients with advanced cancer, according to a Penn Medicine study published today in JAMA Oncology.

A simple set of decision-support tools combined with institutional buy-in can help increase the number of cancer patients who engage in treatment to help them quit tobacco, data from researchers in the Abramson Cancer Center at the University of Pennsylvania show.

Many elderly patients with metastatic renal cell carcinoma (RCC)—who are often underrepresented in clinical trials to treat the kidney cancer—are seeing overall survival benefits from treatment with targeted therapies, according to a new study from Penn Medicine researchers published this month in JAMA Network Open.

From understanding the genetics of cancer cells to improving cellular therapies and incorporating new methods of radiation therapy, a $12 million grant will help researchers at the Abramson Cancer Center at the University of Pennsylvania pursue the next generation of cancer treatments.

In largest study of its kind, Penn researchers compare overall adverse events of proton and photon therapies.

A specialized pain management program for patients who underwent robotic surgery for urologic cancers resulted in just eight percent going home with narcotics after discharge, compared to 100 percent who would have received them without this enhanced recovery protocol.